Adial Pharmaceuticals Inc logo

Adial Pharmaceuticals Inc - Warrants (31/07/2023

(Warrants)
NAS:ADILW (USA)   Warrants (31/07/2023)
$ 0.00 0 (0%) 03:52 PM EST
At Loss
P/B:
0.77
Volume:
-
Avg Vol (2M):
-
Volume:
-
At Loss
Avg Vol (2M):
-
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for ADILW ( Adial Pharmaceuticals Inc ) from 2018 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Adial Pharmaceuticals stock (ADILW) PE ratio as of Apr 24 2024 is 0. More Details

Adial Pharmaceuticals Inc (ADILW) PE Ratio (TTM) Chart

To

Adial Pharmaceuticals Inc (ADILW) PE Ratio (TTM) Historical Data

Total 0
  • 1
Adial Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data

Adial Pharmaceuticals Inc (ADILW) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Adial Pharmaceuticals Inc logo
Adial Pharmaceuticals Inc
NAICS : 325412 SIC : 2834

Share Class Description:

ADILW: Warrants (31/07/2023)
Description
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.